<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">49</article-id><article-id pub-id-type="doi">10.15690/vramn.v70.i2.1306</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>PROCEEDINGS of the GENERAL MEETING of the Department of Medical Sciences, RAS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МАТЕРИАЛЫ ОБЩЕГО СОБРАНИЯ ОТДЕЛЕНИЯ МЕДИЦИНСКИХ НАУК РАН</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">AUTOIMMUNE DISEASES OF DIGESTIVE SYSTEM</article-title><trans-title-group xml:lang="ru"><trans-title>АУТОИММУННЫЕ ЗАБОЛЕВАНИЯ ОРГАНОВ ПИЩЕВАРИТЕЛЬНОЙ СИСТЕМЫ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ivashkin</surname><given-names>V. T.</given-names></name><name xml:lang="ru"><surname>Ивашкин</surname><given-names>В. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор медицинских наук, профессор, академик РАН, заведующий кафедрой про-педевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. СеченоваАдрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1, тел.: +7 (499) 248-35-91</p></bio><email>2135833@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sheptulina</surname><given-names>A. F.</given-names></name><name xml:lang="ru"><surname>Шептулина</surname><given-names>А. Ф.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант кафедры пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. СеченоваАдрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1</p></bio><email>sheptulina.anna@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Raikhel'son</surname><given-names>K. L.</given-names></name><name xml:lang="ru"><surname>Райхельсон</surname><given-names>К. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат медицинских наук, доцент кафедры гастроэнтерологии и диетологии СЗГМУ им. И.И. МечниковаАдрес: 197110, Санкт-Петербург, пр. Динамо, д. 3</p></bio><email>kraikhelson@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Losik</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Лосик</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант кафедры пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. СеченоваАдрес:119991, Москва, ул. Погодинская, д. 1, стр. 1</p></bio><email>kollezion@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ivashkin</surname><given-names>K. V.</given-names></name><name xml:lang="ru"><surname>Ивашкин</surname><given-names>К. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат медицинских наук, ассистент кафедры пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. СеченоваАдрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1</p></bio><email>2135833@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Okhlobystin</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Охлобыстин</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. СеченоваАдрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1</p></bio><email>okhlobystin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Baranskaya</surname><given-names>E. K.</given-names></name><name xml:lang="ru"><surname>Баранская</surname><given-names>Е. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. Сеченова Адрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1</p></bio><email>ebaranskaya@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Polyektova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Полуэктова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат медицинских наук, врач-гастроэнтеролог отделения хронических забо-леваний кишечника и поджелудочной железы клиники пропедевтики внутренних болезней, гастроэнтерологии и гепатологии им. В.Х. Василенко УКБ № 2 Первого МГМУ им. И.М. СеченоваАдрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1</p></bio><email>polouektova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shifrin</surname><given-names>O. S.</given-names></name><name xml:lang="ru"><surname>Шифрин</surname><given-names>О. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. Сеченова, заведующий отделением хронических заболеваний кишечника и поджелудочной железы клиники пропедевтики внутренних болезней, гастроэнтерологии и гепато-логии им. В.Х. Василенко УКБ № 2 Первого МГМУ им. И.М. СеченоваАдрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1</p></bio><email>oleg_shifrin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Russian Federation</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская Федерация</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.I. Mechnikov North-Western State Medical University, Saint-Petersburg, Russian Federation</institution></aff><aff><institution xml:lang="ru">Северо-Западный государственный медицинский университет им. И.И. Мечникова, Санкт-Петербург, Российская Федерация</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-04-08" publication-format="electronic"><day>08</day><month>04</month><year>2015</year></pub-date><volume>70</volume><issue>2</issue><issue-title xml:lang="en">Vestnik Rossiiskoi akademii medetsinskikh nauk / Annals of the Russian academy of medical sciences</issue-title><issue-title xml:lang="ru">Вестник Российской академии медицинских наук</issue-title><fpage>139</fpage><lpage>151</lpage><history><date date-type="received" iso-8601-date="2015-08-07"><day>07</day><month>08</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2015, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2015, Издательство "Педиатръ"</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2016-04-08"/></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/49">https://vestnikramn.spr-journal.ru/jour/article/view/49</self-uri><abstract xml:lang="en"><p><italic>Autoimmune diseases of digestive system refer to pathological conditions, caused by autoimmune mechanisms, and their etiology remains unknown. This is a group of relatively rare diseases, however, during the last years a marked tendency towards the raise in incidence and prevalence is observed, which led to an increase in number of clinical investigations on etiology, pathogenesis, and, accordingly, development of new diagnostic methods and therapies. Results of such trials shown, for example, that the pathogenesis of chronic cholestatic liver diseases is associated with nuclear receptors function, while the main etiological and pathogenic factor of inflammatory bowel diseases represents gut microbiota. Despite new achievements in autoimmune diseases of digestive system research, therapies are low effective and are accompanied by a huge number of adverse events. The fact that these diseases may lead to malignant tumors is also worth noting. For example, patients with primary sclerosing cholangitis have a 160 times higher risk of cholangiocellular carcinoma, while 10–14% of patients with celiac disease may develop malignancies of esophagus, small and large intestine. Thus, these diseases require further investigation with a purpose of more accurate diagnostic methods for the detection of disease at early stages and new effective and safe therapies development.</italic></p><p> </p></abstract><trans-abstract xml:lang="ru"><p><italic>К категории аутоиммунных заболеваний органов желудочно-кишечного тракта (ЖКТ) относят заболевания с иммунологическими механизмами развития, этиология которых до настоящего времени остается неизвестной. Это группа относительно редких болезней, однако в последние годы отмечена отчетливая тенденция к росту их частоты и распространенности, что повлекло за собой увеличение числа исследований, посвященных этиологии, патогенезу, а, следовательно, и созданию новых методов диагностики и схем лечения аутоиммунных заболеваний органов ЖКТ. В результате таких работ, к примеру, были получены данные об участии в патогенезе хронических холестатических заболеваний печени ядерных рецепторов, а также об основополагающей роли кишечной микрофлоры в формировании воспалительных заболеваний кишечника.</italic> <italic>Несмотря на достижения в изучении аутоиммунных заболеваний органов ЖКТ, имеющиеся в настоящее время стратегии терапии остаются малоэффективными и сопряжены с развитием большого числа нежелательных явлений. Нельзя не отметить и тот факт, что многие аутоиммунные заболевания органов ЖКТ являются фоном для развития злокачественных новообразований. Например, у пациентов с первичным склерозирующим холангитом риск возникновения холангиоцеллюлярной карциномы повышен в 160 раз, а у пациентов с целиакией злокачественные новообразования пищевода, тонкой и толстой кишки встречаются в 10–14% случаев. Таким образом, данная группа болезней нуждается в дополнительном изучении с целью создания более точных методов диагностики, позволяющих идентифицировать заболевания на ранних стадиях развития, а также новых более эффективных и безопасных стратегий лечения.</italic></p><p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>autoimmune diseases</kwd><kwd>digestive system</kwd><kwd>nuclear receptors</kwd><kwd>autoantibodies</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аутоиммунные заболевания</kwd><kwd>органы пищеварительной системы</kwd><kwd>ядерные рецепторы</kwd><kwd>аутоантитела</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Toh B.H. Diagnosis and classification of autoimmune gastritis. Auto-immun Rev. 2014; 13 (4–5): 459–462.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Smyk D.S., Koutsoumpas A.L., Mytilinaiou M.G., Rigopoulou E.I., Sakkas L.I., Bogdanos D.P. Helicobacter pylori and autoimmune disease: cause or bystander. World J. Gastroenterol. 2014; 20 (3): 613–629.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.Varbanova M., Frauenschläger K., Malfertheiner P. Chronic gastritis an update. Best Pract. Res. Clin. Gastroenterol. 2014; 28 (6): 1031–1042.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.Whittingham S., Mackay I.R. Autoimmune gastritis: historical antecedents, outstanding discoveries, and unresolved problems. Int. Rev. Immunol. 2005; 24 (1–2): 1–29.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.Lee J.Y., Kim N., Lee H.S., Oh J.C., Kwon Y.H., Choi Y.J., Yoon K.C. Correlations among endoscopic, histologic and serologic diagnoses for the assessment of atrophic gastritis. J. Cancer Prev. 2014; 19 (1): 47–55.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.Polydorides A.D. Pathology and differential diagnosis of chronic, noninfectious gastritis. Semin Diagn. Pathol. 2014; 31 (2): 114–123.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.Vannella L., Lahner E., Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal. World J. Gastroenterol. 2012; 18 (12): 1279–1285.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Egorov V.I., Karmazanovskii G.G., Shchegolev A.I. Autoimmune pancreatitis. Can the preoperative diagnosis? Klinicheskaya i eksperimental'naya gastroenterologiya = Clinical and experimental gastroenterology. 2007;6:13–20.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.Nishimori I., Tamakoshi A., Otsuki M. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. J. Gastroenterol. 2007; 42 (Suppl. 18): 6–8.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.Matsubayashi H., Kakushima N., Takizawa K., Tanaka M., Imai K., Hotta K., Ono H. Diagnosis of autoimmune pancreatitis. World J. Gastroenterol. 2014; 20 (44): 16559–16569.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.Asada M., Nishio A., Uchida K., Kido M., Ueno S., Uza N., Kiriya K., Inoue S., Kitamura H., Ohashi S., Tamaki H., Fukui T., Matsuura M., Kawasaki K., Nishi T. Watanabe N. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas. 2006; 33 (1): 20–26.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.Frulloni L., Lunardi C., Simone R., Dolcino M., Scattolini C., Falconi M., Benini L., Vantini I., Corrocher R., Puccetti A. Identification of a novel antibody associated with autoimmune pancreatitis. N. Engl. J. Med. 2009; 361 (22): 2135–2142.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.Yamamoto M., Naishiro Y., Suzuki C., Kokai Y., Suzuki R., Honda S., Abe T., Takahashi H., Shinomura Y. Proteomics analysis in 28 patients with systemic IgG4 related plasmacytic syndrome. Rheumatol. Int. 2010; 30 (4): 565–568.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.Hart P.A., Zen Y., Chari S.T. Recent Advances in Autoimmune Pancreatitis. Gastroenterology. 2015; 148 (3). Doi: http://dx.doi. org/10.1053/j.gastro.2015.03.010.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.Chang M.C., Liang P.C., Jan S., Yang C.Y., Tien Y.W., Wei S.C., Wong J.M., Chang Y.T. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19–9 levels. Pancreatology. 2014; 14 (5): 366–372.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.Shimosegawa T., Chari S.T., Frulloni L., Kamisawa T., Kawa S., Mino-Kenudson M., Kim M.H., Kloppel G., Lerch M.M., Lohr M., Notohara K., Okazaki K., Schneider A. and Zhang L. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011; 40: 352–358.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17.Chari S.T. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria. J. Gastroenterol. 2007; 42 (Suppl. 18): 39–41.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18.Hart P.A, Kamisawa T., Brugge W.R., Chung J.B., Culver E.L., Czakó L., Frulloni L., Go V.L., Gress T.M., Kim M.H., Kawa S., Lee K.T., Lerch M.M., Liao W.C., Löhr M., Okazaki K., Ryu J.K., Schleinitz N., Shimizu K., Shimosegawa T., Soetikno R., Webster G., Yadav D., Zen Y., Chari S.T. Long term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013; 62 (12): 1771–1776.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19.Huggett M.T., Culver E.L., Kumar M., Hurst J.M., Rodriguez-Jus-to M., Chapman M.H., Johnson G.J., Pereira S.P., Chapman R.W., Webster G.J., Barnes E. Type 1 autoimmune pancreatitis and IgG4 related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am. J. Gastroenterol. 2014; 109 (10): 1675–1683.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20.Leishner U. Autoimmunnye zabolevaniya pecheni i perekrestnyi sindrom [Autoimmune Liver Disease and Cross Syndrome]. Moscow, Anakharsis, 2005. 54 p.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21.Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.Ch., Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 2013; 58: 593–608.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22.Yang F., Wang Q., Jia J., Ma X.J. Autoimmune Hepatitis: East Meets West. Gastroenterol. Hepatol. 2015; 30. Doi: 10.1111/jgh.12952.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23.Oo Y.H., Hubscher S.G., Adams D.H. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol. Int. 2010; 4 (2): 475–493.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24.Couto C.A., Bittencourt P.L., Porta G., Abrantes–Lemos C.P., Carrilho F.J., Guardia B.D., Cançado E.L. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology. 2014; 59: 592–600.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25.Gatselis N.K., Zachou K., Koukoulis G.K., Dalekos G.N. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinic-laboratory and histological characteristics. World J. Gastroenterol. 2015; 21 (1): 60–83.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26.Manns, M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Verga- ni G., Vergani D., Vierling J.M. Diagnosis and management of autoimmune hepatitis. J. Hepatol. 2010; 51 (6): 2193–2213.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27.Danielsson Borssén Å., Almer S., Prytz H., Wallerstedt S., Friis- Liby I.L., Bergquist A., Nyhlin N., Hultcrantz R., Sangfelt P., Weiland O., Lindgren S., Verbaan H., Werner M. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis a long term follow up study in 634 Swedish patients. Scand. J. Gastroenterol. 2015; 50 (2): 217–223.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28.Corpechot C., Chretien Y., Chazouilleres O., Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J. Hepatol. 2010; 53 (1): 62–69.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29.Muratori L., Granito A., Muratori P., Pappas G., Bianchi F.B. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin. Liver Dis. 2008; 12: 261–276.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30.Kawata K., Kobayashi Y., Gershwin M., Bowlus Ch.L. The Immuno-physiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin. Rev. Allerg. Immunol. 2012; 43: 230–241.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31.Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J. Primary biliary cirrhosis. Hepatology. 2009; 50 (1): 291–308.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32.Mayo M.J. Natural history of primary biliary cirrhosis. Clin. Liver Dis. 2008; 12 (2): 277–288.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33.Ivashkin V.T., Shirokova E.N., Maevskaya M.V., Pavlov Ch.S., Shifrin O.S., Maev I.V., Trukhmanov A.S. Clinical guidelines of the Russian Gastroenterological Association and the Russian Society for the Study of the Liver on the diagnosis and treatment of cholestasis. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii = Russian journal of gastroenterology, hepatology and colopractyology. 2015;25(2):40–55.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34.EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. European Association for the Study of the Liver. J. Hepatol. 2009; 51: 237–267.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35.Lammers W.J., van Buuren H.R., Hirschfield G.M., Janssen H.L., Invernizzi P., Mason A.L., Invernizzi P., Mason A.L., Ponsioen C.Y. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow up study. Gastroenterology. 2014; 147 (6): 1338–1349.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36.Rong G., Wang H., Bowlus C.L., Wang C., Lu Y., Zeng Z., Qu J., Lou M., Chen Y., An L., Yang Y., Gershwin M.E. Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis. Clin. Rev. Allergy Immunol. 2015; 48 (2): 132–141.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37.Karlsen T.H., Boberg K.M. Update on primary sclerosing cholangitis. J. Hepatol. 2013; 59 (3): 571–582.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38.Ali A.H., Carey E.J. and Lindor K.D. Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis. Res. 2015; 4 (1): 1–6.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>39.Eaton J.E., Talwalkar J.A., Lazaridis K.N., Gores G., Lindor K.D. Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management. Gastroenterology. 2013; 145 (3): 1–33.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>40.Poluektova E.A., Lyashenko O.S., Korolev A.V., Shifrin O.S., Ivashkin V.T. Mechanisms for the interaction of the bacterial cells with the host, and their disorder in patients with inflammatory bowel diseases. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii = Russian journal of gastroenterology, hepatology and colopractyology. 2014;24(5):42–53.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>41.Johansson M.E., Larsson J.M., Hansson G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host microbial interactions. Proc. Natl. Acad. Sci. USA. 2011; 108: 4659–4665.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>42.Sandborn W., Rogler G. The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology. Peprint of Digestive Disease. 2010; 28 (3): 385–568.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>43.Baumgart D.C. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch. Arztebl. Int. 2009; 106 (8): 123–133.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>44.Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., Mitton S., Orchard T., Rutter M., Younge L., Lees C., Ho G.T., Sat-sangi J., Bloom S. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60 (5): 571–607.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>45.Magro F., Langner C., Driessen A., Ensari A., Geboes K., Mantza- ris G.J., Villanacci V., Becheanu G., Borralho Nunes P., Cathomas G., Fries W., Jouret–Mourin A., Mescoli C., de Petris G., Rubio C.A., Shepherd N.A., Vieth M., Eliakim R. European consensus on the histopathology of inflammatory bowel disease. J. Crohn’s Colitis. 2013; 7 (10): 827–851.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>46.Ivashkin V.T., Shelygin Yu.A., Abdulganieva D.I., Abdulkhakov R.A., Alekseeva O.P., Achkasov S.I., Baranovskii A.Yu., Belousova E.A., Golovenko O.V., Grigor'ev E.G., Kostenko N.V., Lapina T.L., Maev I.V., Moskalev A.I., Nizov A.I., Nikolaeva N.N., Osipenko M.F., Pavlenko V.V., Parfenov A.I., Poluektova E.A., Rumyantsev V.G., Timerbulatov V.M., Tertychnyi A.S., Tkachev A.V., Trukhmanov A.S., Khalif A.L., Khubezov D.A., Chashkova E.Yu., Shifrin O.S., Shchukina O.B. Recommendations of the Russian Gastroenterological Association and the Association of Russian Coloproctologists for diagnosis and treatment of adult patients with ulcerative colitis. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii = Russian journal of gastroenterology, hepatology and colopractyology. 2015;25(1):48–65.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>47.Dignass A., Eliakim R., Magro F., Maaser Ch., Chowers Y., Geboes K., Mantzaris G., Reinisch W., Colombel J.F., Vermeire S., Travis S., Lindsay J.O., Van Assche G. Second European evidence based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J. Crohn's Colitis. 2012; 6 (10): 965–990.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>48.Sands B.E. New drugs on the horizon for IBD. Dig. Dis. 2014; 32 (Suppl. 1): 74–81.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>49.Bohr J., Wickbom A., Hegedus A., Nyhlin N., Hultgren H.E., Tysk C. Diagnosis and management of microscopic colitis: current perspectives. Clin. Exp. Gastroenterol. 2014; 7: 273–284.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>50.Schuppan D., Zimmer K.P. The diagnosis and treatment of celiac disease. Dtsch. Arztebl. Int. 2013; 49 (49): 835–846.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>51.Ludvigsson J.F., Bai J.C., Biagi F., Card T.R., Ciacci C., Ciclitira P.J., Green P.H., Hadjivassiliou M., Holdoway A., van Heel D.A., Kaukinen K., Leffler D.A., Leonard J.N., Lundin K.E., McGough N., Davidson M., Murray J.A., Swift G.L., Walker M.M., Zingone F., Sanders D.S. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014; 63 (8): 1210–1228.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>52.Pelkowski T.D., Viera A.J. Celiac disease: diagnosis and management. Am. Fam. Physician. 2014; 89 (2): 99–105.</mixed-citation></ref></ref-list></back></article>
